{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:40:05Z","timestamp":1788090005296,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder characterized by dysregulated systemic immunity. Multiple cytokines had been found involved in the disease pathogenesis. Hence, involvement of multiple systems in iMCD complicates diagnosis and efficacy assessments. Although guidelines recommend anti-interleukin-6 (IL-6) agents as the primary treatment, options for second-line therapy remain indeterminate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 65-year-old woman presented with progressive polyneuropathy and nephrotic-range proteinuria ten days after COVID-19 vaccination. Evaluation revealed multicentric lymphadenopathy, elevated IL-6, and plasmacytic-variant CD histopathology (HHV-8 negative). Concurrent Sj\u00f6gren\u2019s syndrome and anti-PLA2R-negative membranous nephropathy were confirmed. After exclusion of POEMS syndrome, iMCD-NOS with intermediate severity was diagnosed. Initial rituximab-cyclophosphamide-dexamethasone therapy resulted in paradoxical neurological worsening despite declining VEGF levels. Anti-IL-6 therapy was inaccessible due to economic constraints. Single-agent rituximab was initiated and continued for nine cycles over 24 months, achieving clinical remission by January 2024 with near-normalization of inflammatory markers, resolution of proteinuria, and neurological recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that rituximab monotherapy can achieve clinical remission in iMCD-NOS with concurrent autoimmune manifestations when anti-IL-6 therapy is unavailable. The delayed response pattern\u2014with biomarker improvement preceding clinical recovery\u2014highlights the importance of serial VEGF monitoring and persistence with B-cell\u2013directed therapy before concluding treatment failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1804654","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:39:48Z","timestamp":1780637988000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Idiopathic multiple castleman disease case combined with severe neuropathy, Sjogren\u2019s syndrome and membrane nephropathy treated by rituximab: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Shu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunguo","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pathology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianling","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","unstructured":"Castleman disease\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/art.43269","article-title":"Expert perspective: Diagnosis and treatment of Castleman disease","volume":"78","author":"Chen","year":"2026","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac481","article-title":"Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: Practical guidance for diagnosis","volume":"62","author":"Gonz\u00e1lez Garc\u00eda","year":"2023","journal-title":"Rheumatol (Oxford England)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12882-020-02191-z","article-title":"Idiopathic multicentric Castleman disease with Sj\u00f6gren's syndrome and secondary membranous nephropathy: A case report and review of the literature","volume":"21","author":"Pan","year":"2020","journal-title":"BMC Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1528465","article-title":"Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients","volume":"16","author":"Feng","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0986","article-title":"A novel predictive model for idiopathic multicentric Castleman disease: The International Castleman Disease Consortium Study","volume":"25","author":"Yu","year":"2020","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ndt\/gfq427","article-title":"Renal involvement in Castleman disease","volume":"26","author":"El Karoui","year":"2011","journal-title":"Nephrol Dialysis Transplant: Off Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-209280","article-title":"Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease","volume":"79","author":"Nishikori","year":"2025","journal-title":"J Clin Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3324\/haematol.2025.288147","article-title":"Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease","volume":"111","author":"Nishikori","year":"2025","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","article-title":"Immunoglobulin G4-related disease and idiopathic multicentric Castleman's disease: Confusable immune-mediated disorders","volume":"61","author":"Sasaki","year":"2022","journal-title":"Rheumatol (Oxford England)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/pin.13185","article-title":"Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease","volume":"72","author":"Nishikori","year":"2022","journal-title":"Pathol Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(13)61499-3","article-title":"Clinical aspects of autoimmune rheumatic diseases","volume":"382","author":"Goldblatt","year":"2013","journal-title":"Lancet (London England)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03494-2","article-title":"Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases","volume":"147","author":"Sun","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12882-021-02423-w","article-title":"Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: A case report and review of the literature","volume":"22","author":"Saiki","year":"2021","journal-title":"BMC Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1038\/s41467-025-61214-1","article-title":"Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways","volume":"16","author":"Smith","year":"2025","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman's disease: A systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027689","article-title":"IFN-\u03b3 promotes the progression of iMCD by activating inflammatory monocytes","volume":"146","author":"Yin","year":"2025","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3347-0","article-title":"Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease","volume":"97","author":"Dong","year":"2018","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19000","article-title":"Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice","volume":"203","author":"Yin","year":"2023","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30257-1","article-title":"Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: A prespecified, open-label, extension analysis of two trials","volume":"7","author":"van Rhee","year":"2020","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107123","article-title":"Potential link between COVID-19 infection\/vaccination and the onsets of TAFRO syndrome and idiopathic multicentric castleman disease","volume":"278","author":"Umeda","year":"2026","journal-title":"Immunol Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/vaccines10101725","article-title":"Idiopathic multicentric Castleman disease occurring shortly after mRNA SARS-CoV-2 vaccine","volume":"10","author":"Hoffmann","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1804654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:39:53Z","timestamp":1780637993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1804654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1804654"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1804654","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1804654"}}